Core Facility Metabolomics and Proteomics

Metabolite levels integrate information from both endogenous (genetic) and exogenous (nutrition, medication, environment) origins. The parallel (semi-) quantitative acquisition of a large set of metabolites (Metabolomics) offers a direct read-out of the biochemical status of cells and biological systems.

Proteomics technologies enable the analysis of the entire protein repertoire (the proteome) of a cell, tissue, or organism at the time of sampling. Proteomics data have profoundly added to our understanding of diseases processes, drug-target interactions and helped to identify many predictive and diagnostic biomarkers.

Proximity extension assays (Olink®) enable targeted detection and quantification of proteins in highly multiplexed formats. Helmholtz Munich hosts the first Core Facility certified for Olink® technology in Germany.

Organization and participation in national and international ring trials.

As part of the CLINSPECT-M consortium, which aims at translating MS-based assays into the clinic in the area of neuro diseases, and as leader of the corresponding workpackage 5 – “Quality Assurance and Standardization” – we organize round robin studies to set the foundation for the development of standardized start-to-finish and fit-for-purpose workflows for clinical specimen.